The endogenous and reactive depression subtypes revisited: integrative animal and human studies implicate multiple distinct molecular mechanisms underlying major depressive disorder

The Genome-Based Therapeutic Drugs for Depression study was funded by a European Commission Framework 6 grant, EC Contract Ref: LSHB-CT-2003–503428. The Biomedical Research Centre for Mental Health at the Institute of Psychiatry, King’s College London and South London, and Maudsley National Health Service Foundation Trust (funded by the National Institute for Health Research, Department of Health, United Kingdom) and GlaxoSmithKline contributed by funding add-on projects at the London Centre. Dr. Uher is supported by the Canada Research Chairs program (http://​www.​chairs-chaires.​gc.​ca/​). RK is supported by an MRC Population Health Scientist Award (MR/K021281/1)